SG Americas Securities
EIDX

SG Americas Securities’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

SG Americas Securities’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,911
Closed -$940K – 3786
2020
Q2 		$997K Buy
20,911
+12,299
+143% +$572K 0.01% 1423
2020
Q1 		$422K Sell
8,612
-8,897
-51% -$453K ﹤0.01% 1974
2019
Q4 		$1M Sell
17,509
-22,848
-57% -$1.13M 0.01% 1256
2019
Q3 		$1.45M Buy
40,357
+36,335
+903% +$1.42M 0.01% 1176
2019
Q2 		$125K Buy
+4,022
New +$109K ﹤0.01% 2689

Other funds holding EIDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

SG Americas Securities's EIDX Position: Q3 2020 in Review

SG Americas Securities sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2020, closing a stake of 20,911 shares — an estimated $940K sold.

SG Americas Securities first reported a position in EIDX in Q2 2019 and held it in 5 quarters. The position peaked at $1.45M in Q3 2019. 91 funds tracked by Wall St. Rank hold EIDX as of Q3 2020.

  • SG Americas Securities reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • SG Americas Securities sold 20,911 Eidos Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $940K.
  • SG Americas Securities first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
  • SG Americas Securities's Eidos Therapeutics, Inc. Common Stock position peaked at $1.45M in Q3 2019.
  • 91 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2020.

Based on SG Americas Securities's 13F filing for Q3 2020, filed 9 Nov 2020.